Bicara Therapeutics Inc. (BCAX) Earnings Call Transcripts

Bicara Therapeutics Inc.'s Latest Earnings Call - May 22, 2026

Bicara Therapeutics Inc. reported significant advancements in their clinical data for FICERA, a bifunctional EGFR-directed antibody, during the ASCO 2026 conference call held on May 22, 2026. The company highlighted a median overall survival of 21.3 months in the pivotal 1,500 mg weekly cohort, with a striking 31% three-year overall survival rate, doubling that of the current standard of care. Management maintained their confidence in the ongoing pivotal Phase III study and indicated plans for a maintenance dosing study, which is expected to begin in Q3 2026, further solidifying their commitment to addressing unmet needs in HPV negative head and neck cancer.

Reported metrics

Guidance from management

Management plans to initiate a maintenance dosing study in Q3 2026, with the goal of providing data on progression-free survival by the time of approval.

What management said

Yes. Thanks, Ryan. In terms of the alternative dosing study, as we've discussed in the past, there'll be a loading dose for 12 weeks of 1,500 milligrams followed by the maintenance phase. And the question regarding Cmax and synergy with pembrolizumab we've modeled as Ryan said exposure response that study states are achieved by the time we get to the Q3 dosing. So when we give 2250 milligram in that study along every...

Yes. I think, Steve, from that perspective, we have continued to update when there's been meaningful changes. And I think, obviously, this is one of them. And so I think we will continue to track against the cohorts. All these patients remain in long-term follow-up. So I think that again, as data continues to mature and inform the story, I think well consistent with what we've done in the past. I think we'll make upd...

What analysts pressed on

Analysts raised questions about the depth of response and its correlation with tumor control, as well as the potential for competition between ongoing studies. Concerns about the safety profile of TGF-beta traps were also discussed, particularly regarding anemia and bleeding events.

Main topics on the call

• Overall Survival Improvement — FICERA demonstrated a median overall survival of 21.3 months in the pivotal 1,500 mg weekly cohort, with a 31% three-year overall survival rate, which is significantly higher than the 15% observed with pembrolizumab mono...
• Durability of Response — The data showed that FICERA achieved a median duration of response of 21.7 months, with deep responses observed in 80% of responders at the 1,500 mg dose. This was highlighted by management who noted, "Deep responders ar...
• Safety Profile — Management reported that FICERA continues to demonstrate a generally well-tolerated safety profile with no new safety signals observed across all cohorts. Bill Schelman noted, "The overall safety profile though has been ...
• Market Opportunity — The head and neck cancer market is projected to exceed $5 billion by 2030, with approximately 50,000 new cases annually in major markets, including 18,000 in the U.S. Management emphasized the significant unmet need for ...

Read the full Bicara Therapeutics Inc. transcript (May 22, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 7 Bicara Therapeutics Inc. earnings call transcripts on record, spanning February 20, 2026 to August 11, 2026. Based on this history, Bicara Therapeutics Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BCAX

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

7

First call

February 20, 2026

Most recent

August 11, 2026

Reporting cadence

quarterly